Login to Your Account

Clinic Roundup

Friday, May 24, 2013
• Lpath Inc., of San Diego, began dosing in a Phase IIa trial of Asonep for renal cell carcinoma in patients that have failed standard VEGF- or mTOR-targeted treatments.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription